WO2008027558A2
(en)
|
2006-08-31 |
2008-03-06 |
Codon Devices, Inc. |
Iterative nucleic acid assembly using activation of vector-encoded traits
|
WO2012048113A2
(en)
|
2010-10-07 |
2012-04-12 |
The General Hospital Corporation |
Biomarkers of cancer
|
WO2012064975A1
(en)
|
2010-11-12 |
2012-05-18 |
Gen9, Inc. |
Protein arrays and methods of using and making the same
|
JP6118725B2
(ja)
|
2010-11-12 |
2017-04-19 |
ジェン9・インコーポレイテッドGen9,INC. |
核酸合成のための方法およびデバイス
|
WO2013012674A1
(en)
|
2011-07-15 |
2013-01-24 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
EP2734621B1
(en)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
LT3594340T
(lt)
|
2011-08-26 |
2021-10-25 |
Gen9, Inc. |
Kompozicijos ir būdai, skirti nukleorūgščių didelio tikslumo sąrankai
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
US9150853B2
(en)
|
2012-03-21 |
2015-10-06 |
Gen9, Inc. |
Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
|
US10081807B2
(en)
|
2012-04-24 |
2018-09-25 |
Gen9, Inc. |
Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
|
EP2841572B1
(en)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetic correction of mutated genes
|
HUE038850T2
(hu)
|
2012-05-25 |
2018-11-28 |
Univ California |
Eljárások és kompozíciók cél-DNS RNS-irányított módosításához és transzkripció RNS-irányított modulálásához
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
LT2864531T
(lt)
|
2012-06-25 |
2019-03-12 |
Gen9, Inc. |
Nukleorūgšties konstravimo ir aukšto produktyvumo sekvenavimo būdai
|
EP2906602B1
(en)
*
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
KR101844123B1
(ko)
|
2012-12-06 |
2018-04-02 |
시그마-알드리치 컴퍼니., 엘엘씨 |
Crispr-기초된 유전체 변형과 조절
|
CN110872583A
(zh)
|
2012-12-12 |
2020-03-10 |
布罗德研究所有限公司 |
用于序列操纵和治疗应用的系统、方法和组合物的递送、工程化和优化
|
EP3434776A1
(en)
|
2012-12-12 |
2019-01-30 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
US10544405B2
(en)
|
2013-01-16 |
2020-01-28 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
EP2954042B1
(en)
|
2013-02-07 |
2017-12-06 |
The General Hospital Corporation |
Tale transcriptional activators
|
EP2971184B1
(en)
|
2013-03-12 |
2019-04-17 |
President and Fellows of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
CN105980575A
(zh)
|
2013-03-14 |
2016-09-28 |
卡里布生物科学公司 |
以核酸为靶的核酸的组合物和方法
|
EP3467125B1
(en)
|
2013-03-15 |
2023-08-30 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
US10760064B2
(en)
*
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
CN115261411A
(zh)
*
|
2013-04-04 |
2022-11-01 |
哈佛学院校长同事会 |
利用CRISPR/Cas系统的基因组编辑的治疗性用途
|
EP3603679B1
(en)
|
2013-06-04 |
2022-08-10 |
President and Fellows of Harvard College |
Rna-guided transcriptional regulation
|
US9267135B2
(en)
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
US10704060B2
(en)
*
|
2013-06-05 |
2020-07-07 |
Duke University |
RNA-guided gene editing and gene regulation
|
SG11201510286QA
(en)
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
JP6625971B2
(ja)
|
2013-06-17 |
2019-12-25 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
配列操作のためのタンデムガイド系、方法および組成物の送達、エンジニアリングおよび最適化
|
KR20160030187A
(ko)
|
2013-06-17 |
2016-03-16 |
더 브로드 인스티튜트, 인코퍼레이티드 |
간의 표적화 및 치료를 위한 CRISPRCas 시스템, 벡터 및 조성물의 전달 및 용도
|
AU2014281027A1
(en)
|
2013-06-17 |
2016-01-28 |
Massachusetts Institute Of Technology |
Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
|
WO2015006498A2
(en)
|
2013-07-09 |
2015-01-15 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
WO2015021426A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US11773400B2
(en)
|
2013-08-22 |
2023-10-03 |
E.I. Du Pont De Nemours And Company |
Methods for producing genetic modifications in a plant genome without incorporating a selectable transgene marker, and compositions thereof
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
US9388430B2
(en)
*
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
EP2877571B1
(en)
|
2013-09-18 |
2018-05-30 |
Kymab Limited |
Methods, cells and organisms
|
US10584358B2
(en)
|
2013-10-30 |
2020-03-10 |
North Carolina State University |
Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
|
US9834791B2
(en)
|
2013-11-07 |
2017-12-05 |
Editas Medicine, Inc. |
CRISPR-related methods and compositions with governing gRNAS
|
CA2932472A1
(en)
|
2013-12-12 |
2015-06-18 |
Massachusetts Institute Of Technology |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
EP3080271B1
(en)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
US9840699B2
(en)
|
2013-12-12 |
2017-12-12 |
President And Fellows Of Harvard College |
Methods for nucleic acid editing
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
MX2016007328A
(es)
|
2013-12-12 |
2017-07-19 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma.
|
WO2015089277A1
(en)
*
|
2013-12-12 |
2015-06-18 |
The Regents Of The University Of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
AU2014370416B2
(en)
*
|
2013-12-26 |
2021-03-11 |
The General Hospital Corporation |
Multiplex guide RNAs
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
CA3075047C
(en)
|
2014-02-11 |
2022-02-01 |
The Regents Of The University Of Colorado, A Body Corporate |
Crispr enable method for multiplex genome editing
|
WO2015134812A1
(en)
|
2014-03-05 |
2015-09-11 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
US9938521B2
(en)
|
2014-03-10 |
2018-04-10 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
EP3981876A1
(en)
|
2014-03-26 |
2022-04-13 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
CN106460003A
(zh)
|
2014-04-08 |
2017-02-22 |
北卡罗来纳州立大学 |
用于使用crispr相关基因rna引导阻遏转录的方法和组合物
|
KR20170005494A
(ko)
|
2014-05-30 |
2017-01-13 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
잠복 바이러스 감염에 대한 치료제를 전달하는 조성물 및 방법
|
JP6784601B2
(ja)
|
2014-06-23 |
2020-11-11 |
ザ ジェネラル ホスピタル コーポレイション |
シークエンシングによって評価されるゲノムワイドでバイアスのないDSBの同定(GUIDE−Seq)
|
US20150376587A1
(en)
*
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
US20170198268A1
(en)
*
|
2014-07-09 |
2017-07-13 |
Gen9, Inc. |
Compositions and Methods for Site-Directed DNA Nicking and Cleaving
|
AU2015288157A1
(en)
|
2014-07-11 |
2017-01-19 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
CA2956224A1
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
US9932566B2
(en)
|
2014-08-07 |
2018-04-03 |
Agilent Technologies, Inc. |
CIS-blocked guide RNA
|
EP3186375A4
(en)
|
2014-08-28 |
2019-03-13 |
North Carolina State University |
NEW CAS9 PROTEINS AND GUIDING ELEMENTS FOR DNA TARGETING AND THE GENOME EDITION
|
WO2016040030A1
(en)
|
2014-09-12 |
2016-03-17 |
E. I. Du Pont De Nemours And Company |
Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
|
WO2016049258A2
(en)
*
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
US20170233762A1
(en)
*
|
2014-09-29 |
2017-08-17 |
The Regents Of The University Of California |
Scaffold rnas
|
AU2015330699B2
(en)
*
|
2014-10-10 |
2021-12-02 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
US11680268B2
(en)
|
2014-11-07 |
2023-06-20 |
Editas Medicine, Inc. |
Methods for improving CRISPR/Cas-mediated genome-editing
|
JP6621820B2
(ja)
*
|
2014-11-14 |
2019-12-18 |
インスティチュート フォー ベーシック サイエンスInstitute For Basic Science |
ゲノムでプログラマブルヌクレアーゼの非標的位置を検出する方法
|
US11352666B2
(en)
|
2014-11-14 |
2022-06-07 |
Institute For Basic Science |
Method for detecting off-target sites of programmable nucleases in a genome
|
CN104531633A
(zh)
*
|
2014-11-18 |
2015-04-22 |
李云英 |
Cas9-scForkI融合蛋白及其应用
|
CN107109422B
(zh)
*
|
2014-11-19 |
2021-08-13 |
基础科学研究院 |
使用由两个载体表达的拆分的Cas9的基因组编辑
|
EP4400584A3
(en)
|
2014-12-03 |
2024-10-16 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
CN107208079B
(zh)
*
|
2014-12-05 |
2021-06-29 |
应用干细胞有限公司 |
整合转基因的位点定向crispr/重组酶组合物和方法
|
CN107249318A
(zh)
|
2014-12-10 |
2017-10-13 |
明尼苏达大学董事会 |
用于治疗疾病的遗传修饰的细胞、组织和器官
|
EP3985115A1
(en)
*
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
EP3230452A1
(en)
*
|
2014-12-12 |
2017-10-18 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
US20180179523A1
(en)
*
|
2014-12-18 |
2018-06-28 |
Integrated Dna Technologies, Inc. |
Crispr-based compositions and methods of use
|
US9840702B2
(en)
*
|
2014-12-18 |
2017-12-12 |
Integrated Dna Technologies, Inc. |
CRISPR-based compositions and methods of use
|
US10190106B2
(en)
|
2014-12-22 |
2019-01-29 |
Univesity Of Massachusetts |
Cas9-DNA targeting unit chimeras
|
WO2016114972A1
(en)
|
2015-01-12 |
2016-07-21 |
The Regents Of The University Of California |
Heterodimeric cas9 and methods of use thereof
|
CN107810270A
(zh)
*
|
2015-01-28 |
2018-03-16 |
先锋国际良种公司 |
Crispr杂合dna/rna多核苷酸及使用方法
|
WO2016123243A1
(en)
|
2015-01-28 |
2016-08-04 |
The Regents Of The University Of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
EP3256487A4
(en)
*
|
2015-02-09 |
2018-07-18 |
Duke University |
Compositions and methods for epigenome editing
|
MX2017010480A
(es)
|
2015-02-18 |
2017-11-13 |
Univ Iowa State Res Found Inc |
Modificacion del sitio de enlace represor transcripcional en el promotor nf-yc4 para contenido de proteina incrementado y resistencia al estres.
|
CA2978314A1
(en)
|
2015-03-03 |
2016-09-09 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
WO2016160389A1
(en)
|
2015-03-27 |
2016-10-06 |
E I Du Pont De Nemours And Company |
Soybean u6 small nuclear rna gene promoters and their use in constitutive expression of small rna genes in plants
|
KR20240038141A
(ko)
|
2015-04-06 |
2024-03-22 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
|
CN107690480B
(zh)
|
2015-04-24 |
2022-03-22 |
爱迪塔斯医药公司 |
Cas9分子/指导rna分子复合物的评价
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
WO2016182959A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
EP3303607A4
(en)
|
2015-05-29 |
2018-10-10 |
North Carolina State University |
Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
WO2016196282A1
(en)
|
2015-05-29 |
2016-12-08 |
Agenovir Corporation |
Compositions and methods for cell targeted hpv treatment
|
EP3303634B1
(en)
|
2015-06-03 |
2023-08-30 |
The Regents of The University of California |
Cas9 variants and methods of use thereof
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
CN108026526B
(zh)
|
2015-06-09 |
2023-05-12 |
爱迪塔斯医药公司 |
用于改善移植的crispr/cas相关方法和组合物
|
WO2016201153A1
(en)
*
|
2015-06-10 |
2016-12-15 |
Firmenich Sa |
Cell lines for screening odorant and aroma receptors
|
EP3307893A4
(en)
|
2015-06-12 |
2019-08-21 |
Lonza Walkersville, Inc. |
PROCESS FOR NUCLEAR REPROGRAMMING WITH SYNTHETIC TRANSCRIPTION FACTORS
|
DK3307872T3
(da)
|
2015-06-15 |
2023-10-23 |
Univ North Carolina State |
Fremgangsmåder og sammensætninger til effektiv indgivelse af nukleinsyrer og rna-baserede antimikrober
|
IL293323B2
(en)
|
2015-06-18 |
2024-01-01 |
Massachusetts Inst Technology |
CRISPR enzyme mutations that reduce unintended effects
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
US11279928B2
(en)
*
|
2015-06-29 |
2022-03-22 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
CA2990699A1
(en)
|
2015-06-29 |
2017-01-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
CA2992580C
(en)
|
2015-07-15 |
2022-09-20 |
Rutgers, The State University Of New Jersey |
Nuclease-independent targeted gene editing platform and uses thereof
|
WO2017015637A1
(en)
|
2015-07-22 |
2017-01-26 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
IL257105B
(en)
|
2015-07-31 |
2022-09-01 |
Univ Minnesota |
Adapted cells and treatment methods
|
WO2017023974A1
(en)
*
|
2015-08-03 |
2017-02-09 |
President And Fellows Of Harvard College |
Cas9 genome editing and transcriptional regulation
|
WO2017024047A1
(en)
*
|
2015-08-03 |
2017-02-09 |
Emendobio Inc. |
Compositions and methods for increasing nuclease induced recombination rate in cells
|
CN108351350B
(zh)
*
|
2015-08-25 |
2022-02-18 |
杜克大学 |
使用rna指导型内切核酸酶改善基因组工程特异性的组合物和方法
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
KR20240090567A
(ko)
*
|
2015-08-28 |
2024-06-21 |
더 제너럴 하스피탈 코포레이션 |
조작된 crispr-cas9 뉴클레아제
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
KR102691636B1
(ko)
*
|
2015-08-31 |
2024-08-02 |
애질런트 테크놀로지스, 인크. |
상동 재조합에 의한 crispr/cas-기반 게놈 편집을 위한 화합물 및 방법
|
WO2017044776A1
(en)
*
|
2015-09-10 |
2017-03-16 |
Texas Tech University System |
Single-guide rna (sgrna) with improved knockout efficiency
|
AU2016319110B2
(en)
*
|
2015-09-11 |
2022-01-27 |
The General Hospital Corporation |
Full interrogation of nuclease DSBs and sequencing (FIND-seq)
|
EP3353296B1
(en)
|
2015-09-24 |
2020-11-04 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
WO2017058751A1
(en)
|
2015-09-28 |
2017-04-06 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
US9850484B2
(en)
|
2015-09-30 |
2017-12-26 |
The General Hospital Corporation |
Comprehensive in vitro reporting of cleavage events by sequencing (Circle-seq)
|
CN111961683A
(zh)
*
|
2015-10-06 |
2020-11-20 |
基础科学研究院 |
用于以高效率从植物原生质体生成基因组工程改造的植物的方法
|
EP3362571A4
(en)
|
2015-10-13 |
2019-07-10 |
Duke University |
GENOMIC ENGINEERING WITH TYPE I CRISPRISMS IN EUKARYOTIC CELLS
|
US10167457B2
(en)
|
2015-10-23 |
2019-01-01 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
WO2017070598A1
(en)
|
2015-10-23 |
2017-04-27 |
Caribou Biosciences, Inc. |
Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
|
EP3371329A4
(en)
|
2015-11-03 |
2019-06-19 |
President and Fellows of Harvard College |
METHOD AND DEVICE FOR VOLUMETRIC IMAGING OF A THREE-DIMENSIONAL NUCLEIC ACID-CONTAINING MATRIX
|
EP3374501B1
(en)
|
2015-11-11 |
2023-07-12 |
Lonza Ltd |
Crispr-associated (cas) proteins with reduced immunogenicity
|
EP3414255B1
(en)
|
2015-11-20 |
2021-09-22 |
Washington University |
Preparative electrophoretic method for targeted purification of genomic dna fragments
|
US10612044B2
(en)
|
2015-11-25 |
2020-04-07 |
National University Corporation Gunma University |
DNA methylation editing kit and DNA methylation editing method
|
US11345931B2
(en)
|
2015-12-14 |
2022-05-31 |
President And Fellows Of Harvard College |
Cas discrimination using tuned guide RNA
|
US11542466B2
(en)
|
2015-12-22 |
2023-01-03 |
North Carolina State University |
Methods and compositions for delivery of CRISPR based antimicrobials
|
IL308706A
(en)
*
|
2015-12-28 |
2024-01-01 |
Novartis Ag |
Preparations and methods for the treatment of hemoglobinopathies
|
IL260532B2
(en)
|
2016-01-11 |
2023-12-01 |
Univ Leland Stanford Junior |
Systems containing chaperone proteins and their uses for controlling gene expression
|
BR112018013663A2
(pt)
|
2016-01-11 |
2019-01-22 |
Univ Leland Stanford Junior |
proteínas quiméricas e métodos de imunoterapia
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
EP4155397B1
(en)
|
2016-02-10 |
2024-06-26 |
The Regents of The University of Michigan |
Detection of nucleic acids
|
EP3417061B1
(en)
|
2016-02-18 |
2022-10-26 |
The Regents of the University of California |
Methods and compositions for gene editing in stem cells
|
US10538750B2
(en)
|
2016-02-29 |
2020-01-21 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by CRISPR proteins
|
BR112018068144A2
(pt)
|
2016-03-15 |
2019-02-12 |
Apse Inc |
métodos e composições para maior produção de rna de fita dupla
|
JP2019515654A
(ja)
|
2016-03-16 |
2019-06-13 |
ザ ジェイ. デヴィッド グラッドストーン インスティテューツ |
肥満及び/又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
US11512311B2
(en)
|
2016-03-25 |
2022-11-29 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
|
WO2017165826A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
CN106701765A
(zh)
*
|
2016-04-11 |
2017-05-24 |
广东赤萌医疗科技有限公司 |
用于hiv感染治疗的多核苷酸及其制备药物应用
|
WO2017180915A2
(en)
*
|
2016-04-13 |
2017-10-19 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
US11236313B2
(en)
|
2016-04-13 |
2022-02-01 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
CN109415761B
(zh)
|
2016-04-25 |
2022-09-20 |
哈佛学院董事及会员团体 |
用于原位分子检测的杂交链反应方法
|
CN107326046A
(zh)
*
|
2016-04-28 |
2017-11-07 |
上海邦耀生物科技有限公司 |
一种提高外源基因同源重组效率的方法
|
BR112018073750A2
(pt)
|
2016-05-20 |
2019-02-26 |
Regeneron Pharmaceuticals, Inc. |
métodos para gerar proteínas de ligação ao antígeno contra um antígeno estranho de interesse e para produzir um animal não humano geneticamente modificado com tolerância reduzida de um antígeno estranho de interesse
|
GB2582731B8
(en)
|
2016-06-02 |
2021-10-27 |
Sigma Aldrich Co Llc |
Using programmable DNA binding proteins to enhance targeted genome modification
|
US20190100732A1
(en)
*
|
2016-06-02 |
2019-04-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Assay for the removal of methyl-cytosine residues from dna
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
EP3473728B1
(en)
*
|
2016-06-15 |
2021-10-20 |
Toolgen Incorporated |
Method for screening targeted genetic scissors by using multiple target system of on-target and off-target activity and use thereof
|
DK3474669T3
(da)
|
2016-06-24 |
2022-06-27 |
Univ Colorado Regents |
Fremgangsmåde til generering af stregkodede kombinatoriske biblioteker
|
MX2019000088A
(es)
|
2016-06-27 |
2019-08-29 |
Broad Inst Inc |
Composiciones y metodos para detectar y tratar la diabetes.
|
US20180004537A1
(en)
|
2016-07-01 |
2018-01-04 |
Microsoft Technology Licensing, Llc |
Molecular State Machines
|
US10669558B2
(en)
|
2016-07-01 |
2020-06-02 |
Microsoft Technology Licensing, Llc |
Storage through iterative DNA editing
|
US11359234B2
(en)
|
2016-07-01 |
2022-06-14 |
Microsoft Technology Licensing, Llc |
Barcoding sequences for identification of gene expression
|
MA45670A
(fr)
|
2016-07-13 |
2019-05-22 |
Vertex Pharma |
Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome
|
WO2018010516A1
(zh)
*
|
2016-07-13 |
2018-01-18 |
陈奇涵 |
一种基因组dna特异性编辑方法和应用
|
EP3491133A4
(en)
*
|
2016-07-26 |
2020-05-06 |
The General Hospital Corporation |
VARIANTS OF CRISPR OF PREVOTELLA AND FRANCISELLA 1 (CPF1)
|
WO2018021855A1
(ko)
*
|
2016-07-28 |
2018-02-01 |
기초과학연구원 |
Cas9 단백질 및 가이드 RNA를 포함하는 안질환 치료용 약학 조성물
|
US10548302B2
(en)
|
2016-07-29 |
2020-02-04 |
Regeneron Pharmaceuticals, Inc. |
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
|
BR112019001887A2
(pt)
|
2016-08-02 |
2019-07-09 |
Editas Medicine Inc |
composições e métodos para o tratamento de doença associada a cep290
|
SG11201900907YA
(en)
|
2016-08-03 |
2019-02-27 |
Harvard College |
Adenosine nucleobase editors and uses thereof
|
CN109804066A
(zh)
|
2016-08-09 |
2019-05-24 |
哈佛大学的校长及成员们 |
可编程cas9-重组酶融合蛋白及其用途
|
US11905549B2
(en)
|
2016-08-10 |
2024-02-20 |
Genahead Bio, Inc. |
Method for modifying target site in genome of eukaryotic cell, and method for detecting presence or absence of nucleic acid sequence to be detected at target site
|
MX2019002004A
(es)
|
2016-08-19 |
2019-10-09 |
Whitehead Inst Biomedical Res |
Metodos para editar la metilacion del adn.
|
WO2018034554A1
(ko)
*
|
2016-08-19 |
2018-02-22 |
주식회사 툴젠 |
인위적으로 조작된 신생혈관형성 조절 시스템
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
IL264639B2
(en)
|
2016-08-24 |
2024-01-01 |
Sangamo Therapeutics Inc |
Regulation of globulin gene expression using transgenic nucleases with zinc neurites
|
SG10201913948PA
(en)
|
2016-08-24 |
2020-03-30 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
WO2018048194A1
(ko)
*
|
2016-09-07 |
2018-03-15 |
울산대학교 산학협력단 |
dCas9 단백질 및 표적 핵산 서열에 결합하는 gRNA를 이용한 핵산 검출의 민감도 및 특이도 향상용 조성물 및 방법
|
JP2019531763A
(ja)
*
|
2016-09-07 |
2019-11-07 |
フラッグシップ パイオニアリング, インコーポレイテッド |
遺伝子発現をモジュレートするための方法および組成物
|
CN107880132B
(zh)
*
|
2016-09-30 |
2022-06-17 |
北京大学 |
一种融合蛋白及使用其进行同源重组的方法
|
EP3523426A4
(en)
|
2016-09-30 |
2020-01-22 |
The Regents of The University of California |
RNA GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHOD FOR USE THEREOF
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
CA3039409A1
(en)
|
2016-10-07 |
2018-04-12 |
Integrated Dna Technologies, Inc. |
S. pyogenes cas9 mutant genes and polypeptides encoded by same
|
US11242542B2
(en)
|
2016-10-07 |
2022-02-08 |
Integrated Dna Technologies, Inc. |
S. pyogenes Cas9 mutant genes and polypeptides encoded by same
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
AU2017341926B2
(en)
|
2016-10-14 |
2022-06-30 |
The General Hospital Corporation |
Epigenetically regulated site-specific nucleases
|
EP3529359B1
(en)
|
2016-10-18 |
2023-12-13 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes for use in therapy
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
US20180282722A1
(en)
*
|
2016-11-21 |
2018-10-04 |
Massachusetts Institute Of Technology |
Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing
|
CA3044101A1
(en)
|
2016-11-22 |
2018-05-31 |
Integrated Dna Technologies, Inc. |
Crispr/cpf1 systems and methods
|
BR112019011509A2
(pt)
|
2016-12-08 |
2020-01-28 |
Intellia Therapeutics Inc |
rnas guias modificados
|
US11293022B2
(en)
|
2016-12-12 |
2022-04-05 |
Integrated Dna Technologies, Inc. |
Genome editing enhancement
|
AU2017378431A1
(en)
|
2016-12-14 |
2019-06-20 |
Ligandal, Inc. |
Compositions and methods for nucleic acid and/or protein payload delivery
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
AU2017388379A1
(en)
*
|
2016-12-28 |
2019-06-06 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and uses thereof
|
EP3565608A4
(en)
|
2017-01-05 |
2020-12-16 |
Rutgers, The State University of New Jersey |
TARGETED GENEDITATION PLATFORM INDEPENDENT OF DNA DOUBLE STRAND BREAKAGE AND USES THEREOF
|
EP3565907B1
(en)
|
2017-01-06 |
2022-05-04 |
Editas Medicine, Inc. |
Methods of assessing nuclease cleavage
|
ES2949801T3
(es)
|
2017-01-09 |
2023-10-03 |
Whitehead Inst Biomedical Res |
Métodos para alterar la expresión génica mediante la perturbación de multímeros de factores de transcripción que estructuran bucles reguladores
|
JP2020505062A
(ja)
*
|
2017-01-17 |
2020-02-20 |
インスティテュート フォー ベーシック サイエンスInstitute For Basic Science |
Dna一本鎖切断による塩基編集非標的位置確認方法
|
CN110199032A
(zh)
|
2017-01-23 |
2019-09-03 |
雷杰纳荣制药公司 |
羟基类固醇17-β脱氢酶13(HSD17B13)变体及其用途
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
KR20190116282A
(ko)
|
2017-02-10 |
2019-10-14 |
지머젠 인코포레이티드 |
복수의 숙주를 위한 다중 dna 구조체의 조립 및 편집을 위한 모듈식 범용 플라스미드 디자인 전략
|
EP3655533A1
(en)
|
2017-02-24 |
2020-05-27 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
US11268082B2
(en)
|
2017-03-23 |
2022-03-08 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable DNA binding proteins
|
CN108660161B
(zh)
*
|
2017-03-31 |
2023-05-09 |
中国科学院脑科学与智能技术卓越创新中心 |
基于CRISPR/Cas9技术的制备无嵌合基因敲除动物的方法
|
AU2018250330A1
(en)
|
2017-04-07 |
2019-09-19 |
Sage Science, Inc. |
Systems and methods for detection of genetic structural variation using integrated electrophoretic DNA purification
|
BR112019021719A2
(pt)
|
2017-04-21 |
2020-06-16 |
The General Hospital Corporation |
Variantes de cpf1 (cas12a) com especificidade para pam alterada
|
CA3059208A1
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Inducible, tunable, and multiplex human gene regulation using crispr-cpf1
|
US11499151B2
(en)
|
2017-04-28 |
2022-11-15 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide RNA molecules
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
AU2018273968A1
(en)
|
2017-05-25 |
2019-11-28 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
CN108977442B
(zh)
*
|
2017-06-05 |
2023-01-06 |
广州市锐博生物科技有限公司 |
用于dna编辑的系统及其应用
|
JP2020527329A
(ja)
|
2017-06-05 |
2020-09-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
B4galt1バリアント及びその使用
|
EP3635104A1
(en)
|
2017-06-09 |
2020-04-15 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
WO2018232114A1
(en)
|
2017-06-14 |
2018-12-20 |
Wisconsin Alumni Research Foundation |
Modified guide rnas, crispr-ribonucleotprotein complexes and methods of use
|
MX2019015188A
(es)
|
2017-06-15 |
2020-08-03 |
Univ California |
Inserciones de adn no virales orientadas.
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
WO2019003193A1
(en)
|
2017-06-30 |
2019-01-03 |
Novartis Ag |
METHODS FOR TREATING DISEASES USING GENE EDITING SYSTEMS
|
WO2019014230A1
(en)
|
2017-07-11 |
2019-01-17 |
Sigma-Aldrich Co. Llc |
USE OF DOMAINS OF PROTEINS INTERACTING WITH NUCLEOSOMES TO IMPROVE THE TARGETED MODIFICATION OF THE GENOME
|
WO2019014564A1
(en)
|
2017-07-14 |
2019-01-17 |
Editas Medicine, Inc. |
SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
|
EP3658573A1
(en)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
AU2018309714A1
(en)
|
2017-07-31 |
2020-01-30 |
Regeneron Pharmaceuticals, Inc. |
Assessment of CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo
|
EP3585160A2
(en)
*
|
2017-07-31 |
2020-01-01 |
Regeneron Pharmaceuticals, Inc. |
Crispr reporter non-human animals and uses thereof
|
BR112020001364A2
(pt)
|
2017-07-31 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
métodos para testar e modificar a capacidade de uma crispr/cas nuclease.
|
CN111278848B
(zh)
|
2017-08-04 |
2023-06-27 |
北京大学 |
特异性识别甲基化修饰dna碱基的tale rvd及其应用
|
EP3666898A4
(en)
|
2017-08-08 |
2021-03-24 |
Peking University |
GENE INACTIVATION PROCESS
|
BR112020003596A2
(pt)
|
2017-08-23 |
2020-09-01 |
The General Hospital Corporation |
nucleases de crispr-cas9 engenheiradas com especificidade de pam alterada
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
EP3585162B1
(en)
|
2017-09-29 |
2023-08-30 |
Regeneron Pharmaceuticals, Inc. |
Rodents comprising a humanized ttr locus and methods of use
|
US11725228B2
(en)
|
2017-10-11 |
2023-08-15 |
The General Hospital Corporation |
Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies
|
CN111757937A
(zh)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
腺苷碱基编辑器的用途
|
CN107602707B
(zh)
*
|
2017-10-17 |
2021-04-23 |
湖北大学 |
一种特异性调节枯草芽孢杆菌外源基因表达的dcas9-ω融合蛋白及其应用
|
MX2020004325A
(es)
|
2017-10-27 |
2020-11-09 |
Univ California |
Reemplazo dirigido de receptores de células t endógenos.
|
EP3704245A1
(en)
|
2017-11-01 |
2020-09-09 |
Novartis AG |
Synthetic rnas and methods of use
|
EP3710583A1
(en)
*
|
2017-11-16 |
2020-09-23 |
Astrazeneca AB |
Compositions and methods for improving the efficacy of cas9-based knock-in strategies
|
US11293019B2
(en)
|
2017-12-22 |
2022-04-05 |
Gflas Life Sciences, Inc. |
Chimeric genome engineering molecules and methods
|
CN109504711A
(zh)
*
|
2018-02-14 |
2019-03-22 |
复旦大学 |
基于CRISPR/cas9和过氧化物酶APEX2系统识别分析特异性基因组位点相互作用DNA的方法
|
WO2019161340A1
(en)
|
2018-02-19 |
2019-08-22 |
Yale University |
Phosphopeptide-encoding oligonucleotide libraries and methods for detecting phosphorylation-dependent molecular interactions
|
CN112020554B
(zh)
|
2018-02-23 |
2024-10-22 |
先锋国际良种公司 |
新颖cas9直系同源物
|
SG11202008956XA
(en)
|
2018-03-14 |
2020-10-29 |
Editas Medicine Inc |
Systems and methods for the treatment of hemoglobinopathies
|
AU2019239880B2
(en)
|
2018-03-19 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using CRISPR/Cas systems
|
KR20200141470A
(ko)
|
2018-04-06 |
2020-12-18 |
칠드런'즈 메디컬 센터 코포레이션 |
체세포 재프로그래밍 및 각인의 조정을 위한 조성물 및 방법
|
CA3097044A1
(en)
|
2018-04-17 |
2019-10-24 |
The General Hospital Corporation |
Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
|
MX2020010974A
(es)
|
2018-04-19 |
2021-01-20 |
Univ California |
Composiciones y métodos para la edición de genes.
|
WO2019213430A1
(en)
*
|
2018-05-03 |
2019-11-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for nicking target dna sequences
|
CN108588123A
(zh)
*
|
2018-05-07 |
2018-09-28 |
南京医科大学 |
CRISPR/Cas9载体组合在制备基因敲除猪的血液制品中的应用
|
CN112654710A
(zh)
|
2018-05-16 |
2021-04-13 |
辛瑟高公司 |
用于指导rna设计和使用的方法和系统
|
US10227576B1
(en)
|
2018-06-13 |
2019-03-12 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
CN110592141B
(zh)
*
|
2018-06-13 |
2023-07-07 |
中国科学院上海有机化学研究所 |
用于调控基因编辑效率的化合物及其应用
|
CA3105658A1
(en)
|
2018-07-13 |
2020-01-16 |
The Regents Of The University Of California |
Retrotransposon-based delivery vehicle and methods of use thereof
|
CA3107002A1
(en)
|
2018-08-15 |
2020-04-30 |
Zymergen Inc. |
Applications of crispri in high throughput metabolic engineering
|
EP3841204A4
(en)
|
2018-08-23 |
2022-05-18 |
Sangamo Therapeutics, Inc. |
CHANGED TARGET SPECIFIC BASE EDITORS
|
WO2020049158A1
(en)
|
2018-09-07 |
2020-03-12 |
Astrazeneca Ab |
Compositions and methods for improved nucleases
|
EP3861120A4
(en)
|
2018-10-01 |
2023-08-16 |
North Carolina State University |
RECOMBINANT TYPE I CRISPR-CAS SYSTEM
|
WO2020076976A1
(en)
|
2018-10-10 |
2020-04-16 |
Readcoor, Inc. |
Three-dimensional spatial molecular indexing
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
US11739320B2
(en)
|
2018-11-05 |
2023-08-29 |
Wisconsin Alumni Research Foundation |
Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
|
EP3894550A4
(en)
|
2018-12-14 |
2023-01-04 |
Pioneer Hi-Bred International, Inc. |
NEW CRISPR-CAS SYSTEMS FOR GENOME EDITING
|
US11690362B2
(en)
|
2018-12-20 |
2023-07-04 |
Regeneran Pharmaceuticals, Inc. |
Nuclease-mediated repeat expansion
|
US20220106584A1
(en)
|
2019-01-14 |
2022-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
EP3921417A4
(en)
|
2019-02-04 |
2022-11-09 |
The General Hospital Corporation |
ADENINE DNA BASE EDITOR VARIANTS WITH REDUCED OFF-TARGET RNA EDITING
|
WO2020163856A1
(en)
|
2019-02-10 |
2020-08-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Modified mitochondrion and methods of use thereof
|
AU2020231380A1
(en)
|
2019-03-07 |
2021-09-23 |
The Regents Of The University Of California |
CRISPR-Cas effector polypeptides and methods of use thereof
|
IL286359B2
(en)
|
2019-03-18 |
2024-06-01 |
Regeneron Pharma |
A CRISPR/CAS knock-out screening platform for uncovering genetic vulnerabilities associated with tau aggregation
|
EP3768826B1
(en)
|
2019-03-18 |
2023-12-13 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
|
BR112021018607A2
(pt)
|
2019-03-19 |
2021-11-23 |
Massachusetts Inst Technology |
Métodos e composições para editar sequências de nucleotídeos
|
CN118064502A
(zh)
|
2019-04-03 |
2024-05-24 |
瑞泽恩制药公司 |
用于将抗体编码序列插入到安全港基因座中的方法和组合物
|
EP3775201B1
(en)
|
2019-04-04 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for scarless introduction of targeted modifications into targeting vectors
|
IL286905B2
(en)
|
2019-04-04 |
2024-06-01 |
Regeneron Pharma |
Non-human animals containing the human coagulation factor 12 locus
|
JP2022528722A
(ja)
|
2019-04-12 |
2022-06-15 |
アストラゼネカ・アクチエボラーグ |
改善された遺伝子編集のための組成物及び方法
|
CA3137761A1
(en)
|
2019-06-04 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
BR112021022722A2
(pt)
|
2019-06-07 |
2022-01-04 |
Regeneron Pharma |
Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente
|
EP3813522A1
(en)
|
2019-06-14 |
2021-05-05 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
EP3783104A1
(en)
*
|
2019-08-20 |
2021-02-24 |
Kemijski Institut |
Coiled-coil mediated tethering of crispr-cas and exonucleases for enhanced genome editing
|
US20210079394A1
(en)
|
2019-09-13 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles
|
AU2020352552A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
|
LT3812472T
(lt)
|
2019-10-21 |
2023-03-10 |
Albert-Ludwigs-Universität Freiburg |
Objektyviai nešališkas tyrimas in vitro sąlygomis, skirtas vienos arba daugiau tikslinių programuojamų nukleazių ląstelėje nespecifinės sąveikos aktyvumui profiliuoti (abnoba-seq)
|
US11331333B2
(en)
|
2019-11-08 |
2022-05-17 |
Georg-August-Universität Göttingen Stiftung Öffentichen Rechts, Universitätsmadizin |
Treatment of aberrant fibroblast proliferation
|
JP2022553573A
(ja)
|
2019-11-08 |
2022-12-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
X連鎖性若年網膜分離療法のためのcrisprおよびaav戦略
|
US20230042198A1
(en)
*
|
2019-11-25 |
2023-02-09 |
La Jolla Institute For Immunology |
Methods and Compositions for Modulationg Heterochromatin Dysfunction, Genomic Instability, and Associate Conditions
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
TW202136509A
(zh)
|
2019-12-11 |
2021-10-01 |
美商英特利亞醫療公司 |
用於基因編輯之經修飾引導rna
|
CN111088357B
(zh)
*
|
2019-12-31 |
2022-09-20 |
深圳大学 |
针对escc的肿瘤标志物及其应用
|
EP4093864A4
(en)
*
|
2020-01-24 |
2024-04-10 |
The General Hospital Corporation |
UNCONSTRAINED GENOME TARGETING WITH GENETICALLY MODIFIED CRISPR-CAS9 VARIANTS NEARLY PAM-FREE
|
EP4093863A4
(en)
*
|
2020-01-24 |
2024-04-10 |
The General Hospital Corporation |
CRISPR-CAS ENZYMES WITH IMPROVED ON-TARGET ACTIVITY
|
AU2021219795A1
(en)
|
2020-02-12 |
2022-08-25 |
Massachusetts Eye And Ear Infirmary |
Haplotype-based treatment of RP1 associated retinal degenerations
|
JP2023515671A
(ja)
|
2020-03-04 |
2023-04-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
免疫療法に対する腫瘍細胞の感作のための方法及び組成物
|
EP4125348A1
(en)
|
2020-03-23 |
2023-02-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
GB2623891B
(en)
*
|
2020-04-09 |
2024-10-23 |
Verve Therapeutics Inc |
Base editing of ANGPTL3 and methods of using same for treatment of disease
|
BR112022022384A2
(pt)
*
|
2020-05-04 |
2022-12-13 |
Editas Medicine Inc |
Seleção por knock-in de gene essencial
|
US20230193212A1
(en)
|
2020-05-06 |
2023-06-22 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
JP2023525304A
(ja)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート,インコーポレーテッド |
標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
|
US20230279438A1
(en)
|
2020-05-13 |
2023-09-07 |
Inserm (Institut National De La Santé Et La Recherche Médicale) |
Base editing approaches for the treatment of betahemoglobinopathies
|
WO2021246165A1
(ja)
*
|
2020-06-03 |
2021-12-09 |
国立大学法人広島大学 |
Oasis遺伝子の脱メチル化のための核酸及びそれを用いた脱メチル化方法
|
EP4179079A1
(en)
|
2020-07-10 |
2023-05-17 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
IL300374A
(en)
|
2020-08-11 |
2023-04-01 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
A method for treating diseases related to WWOX
|
KR102674574B1
(ko)
*
|
2020-09-02 |
2024-06-13 |
한국과학기술연구원 |
Cas9을 위한 신규 tracrRNA 시스템
|
CN116391040A
(zh)
|
2020-10-13 |
2023-07-04 |
法国国家科学研究中心(Cnrs) |
结合接合和Crispr/Cas系统的靶向抗菌质粒及其用途
|
CN112430622A
(zh)
*
|
2020-10-26 |
2021-03-02 |
扬州大学 |
一种FokI和dCpf1融合蛋白表达载体及其介导的定点基因编辑方法
|
RU2762831C1
(ru)
*
|
2020-10-26 |
2021-12-23 |
Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт сельскохозяйственной биотехнологии" (ФГБНУ ВНИИСБ) |
Молекула рнк-проводника для геномного редактирования протомоторной области гена vrn-a1 однодольных зерновых с применением системы crispr/cas9
|
US20240002839A1
(en)
|
2020-12-02 |
2024-01-04 |
Decibel Therapeutics, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
KR20220082186A
(ko)
|
2020-12-10 |
2022-06-17 |
한세준 |
유,무선 충전이 가능한 보조배터리형 uv-led살균기
|
US20240067954A1
(en)
|
2021-01-05 |
2024-02-29 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
WO2022180153A1
(en)
|
2021-02-25 |
2022-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Allele-specific genome editing of the nr2e3 mutation g56r
|
KR20220124652A
(ko)
|
2021-03-03 |
2022-09-14 |
중앙대학교 산학협력단 |
CRISPR/Cas9 시스템을 이용한 유전체 단일염기 편집 방법 및 이의 용도
|
CN113846019B
(zh)
*
|
2021-03-05 |
2023-08-01 |
海南师范大学 |
一种海洋微拟球藻靶向表观基因组遗传调控方法
|
EP4095243A1
(en)
|
2021-05-25 |
2022-11-30 |
European Molecular Biology Laboratory |
System for hybridization-based precision genome cleavage and editing, and uses thereof
|
WO2022248645A1
(en)
|
2021-05-27 |
2022-12-01 |
Astrazeneca Ab |
Cas9 effector proteins with enhanced stability
|
WO2022261292A1
(en)
|
2021-06-10 |
2022-12-15 |
Intellia Therapeutics, Inc. |
Modified guide rnas comprising an internal linker for gene editing
|
CA3227105A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
EP4387992A1
(en)
|
2021-08-20 |
2024-06-26 |
Wisconsin Alumni Research Foundation |
Nonviral generation of genome edited chimeric antigen receptor t cells
|
WO2023039586A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
WO2023052366A1
(en)
|
2021-09-28 |
2023-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of beta-hemoglobinopathies
|
WO2023052508A2
(en)
|
2021-09-30 |
2023-04-06 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
IL311570A
(en)
|
2021-10-14 |
2024-05-01 |
Arsenal Biosciences Inc |
Immune cells with common expression chain and logic gate systems
|
CA3234811A1
(en)
|
2021-10-20 |
2023-04-27 |
Steven Goldman |
Rejuvenation treatment of age-related white matter loss
|
EP4423271A2
(en)
|
2021-10-28 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
IL312508A
(en)
|
2021-11-03 |
2024-07-01 |
Intellia Therapeutics Inc |
Polynucleotides, compounds and methods for genome editing
|
EP4441089A1
(en)
|
2021-12-01 |
2024-10-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer
|
WO2023108047A1
(en)
|
2021-12-08 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023141487A1
(en)
*
|
2022-01-20 |
2023-07-27 |
Inari Agriculture Technology, Inc. |
Improved soybean explant preparation and transformation
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023144104A1
(en)
|
2022-01-25 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of βeta-thalassemia
|
AU2023216255A1
(en)
|
2022-02-02 |
2024-07-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
|
WO2023152351A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstream of meg3 in the dlk1/dio3 locus
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023217888A1
(en)
|
2022-05-10 |
2023-11-16 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the cd39 (cag>tag) mutation in patients suffering from βeta-thalassemia
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
WO2023235726A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr interference therapeutics for c9orf72 repeat expansion disease
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024018056A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the ivs2-1 (g>a) mutation in patients suffering from βeta-thalassemia
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
TW202426641A
(zh)
|
2022-08-19 |
2024-07-01 |
美商圖恩療法股份有限公司 |
以靶向基因抑制來調節b型肝炎病毒之組合物、系統和方法
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
WO2024084025A1
(en)
|
2022-10-21 |
2024-04-25 |
Keygene N.V. |
Rna transfection in plant cells with modified rna
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
US20240173426A1
(en)
|
2022-11-14 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
CN115820603B
(zh)
*
|
2022-11-15 |
2024-07-05 |
吉林大学 |
一种基于dCasRx-NSUN6单基因特异性M5C修饰编辑方法
|
WO2024121354A1
(en)
|
2022-12-08 |
2024-06-13 |
Keygene N.V. |
Duplex sequencing with covalently closed dna ends
|
WO2024131940A1
(zh)
*
|
2022-12-23 |
2024-06-27 |
益杰立科(上海)生物科技有限公司 |
融合物及其用途
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
WO2024165484A1
(en)
|
2023-02-06 |
2024-08-15 |
Institut National de la Santé et de la Recherche Médicale |
Enrichment of genetically modified hematopoietic stem cells through multiplex base editing
|
CN116376975B
(zh)
*
|
2023-02-27 |
2024-05-14 |
中国科学院脑科学与智能技术卓越创新中心 |
激活异染色质基因的方法及应用
|
WO2024186890A1
(en)
|
2023-03-06 |
2024-09-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for hepatitis b virus (hbv) genome editing
|
CN118684781A
(zh)
*
|
2023-03-21 |
2024-09-24 |
深圳赫兹生命科学技术有限公司 |
GnRH-VLP重组去势疫苗及其制备方法
|
WO2024201368A1
(en)
|
2023-03-29 |
2024-10-03 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
WO2024209000A1
(en)
|
2023-04-04 |
2024-10-10 |
Keygene N.V. |
Linkers for duplex sequencing
|